Monitoring Patients on Therapy for Recurrent Endometrial Cancer

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Trial data support potential treatment options with durvalumab-based regimens for advanced or recurrent endometrial cancer.

Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.